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OBJECTIVE: The aim of the study was to evaluate the cost-
effectiveness of peginterferon alfa-2a (40KD) for the treatment
of patients with HBeAg-negative chronic hepatitis B in Poland.
The analysis compared two strategies: peginterferon alfa-2a
(40KD) vs. lamivudine for 48 weeks (short-term analysis) or
peginterferon alfa-2a (40KD) for 48 weeks vs. lamivudine for 4
years (long-term analysis). METHODS: The analysis was per-
formed from the Polish payer perspective using a state-transition
Markov model. Quality-adjusted life years (QALYs) was
adopted as a measure of effectiveness. Efﬁcacy with peginter-
feron alfa-2a (40KD) and lamivudine after 48 weeks of treat-
ment was obtained from a randomized controlled trial
(Marcellin et al. NEJM 2004;351(12):32–43). Long-term
lamivudine efﬁcacy, health state transition probabilities and
utility estimates were obtained from the published literature.
Direct medical costs, i.e. cost of drugs and procedures in the
treatment of hepatitis B and its complications (cirrhosis, hepa-
tocellular carcinoma, liver transplantation) were obtained from
Polish sources. Costs and beneﬁts were discounted at a 3%
annual rate. RESULTS: Peginterferon alfa-2a 40(KD) vs. lamivu-
dine for 48 weeks (short-term analysis) increased QALYs by
0,89. The mean treatment cost in the short-term analysis was
17,743 € (1€ = 4.035 PLN) and 12,522 € per patients for pegin-
terferon alfa-2a and lamivudine, respectively. The incremental
cost-effectiveness ratio (ICER) was 9316 €/QALY gained. In the
long-term analysis, peginterferon alfa-2a (40KD) increased
QALYs by 0,75. The mean cost of treatment was 17 €398 for
peginterferon alfa-2a (40KD) and €13,890 for lamivudine per
patient. The incremental cost-effectiveness ratio (ICER) was
€7643 per QALY gained. CONCLUSIONS: The ICER for pegin-
terferon alfa-2a evaluated in the short-term analysis as well as
in the long-term analysis did not exceed €14,870 (cost of one
year dialysis in Poland). Thus, the procedure appears to be cost-
effective in Poland.
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OBJECTIVES: Primary (ﬁrst and subsequent cycles) prophylaxis
with ﬁlgrastim or pegﬁlgrastim has been recommended in 2006
clinical guidelines when the risk of febrile neutropenia (FN) is
about 20%. Recent studies reported signiﬁcantly greater reduc-
tion of FN with pegﬁlgrastim. In clinical practice, ﬁlgrastim has
often been used for fewer than the recommended 11 days (e.g.,
5–6 days), which has been shown to compromise the clinical out-
comes. The study purpose was to evaluate the cost-effectiveness
of pegﬁlgrastim vs. ﬁlgrastim (11- or 6-day) primary prophylaxis
in women with breast cancer (stage I-III) receiving chemother-
apy with moderate to high FN risk in Germany. METHODS: We
constructed a decision-analytic model from a health care payer’s
perspective. Costs included drugs, drug administration, FN-
related hospitalizations and subsequent costs, and were based on
Rote Liste (list price) and DRG Tariff. Effectiveness was mea-
sured as FN avoided and life-year-gained (LYG). FN risk (varied
by days of ﬁlgrastim), FN case-fatality, relative dose intensity
(RDI), and the impact of RDI on survival were based on a com-
prehensive literature review and expert panel validation. Breast
cancer mortality and all-cause mortality were from ofﬁcial sta-
tistics. Sensitivity analyses were conducted on key variables.
RESULTS: Pegﬁlgrastim use avoided more FN events, produced
greater LYG and was less expensive than 11-day ﬁlgrastim. Com-
pared with 6-day ﬁlgrastim, pegﬁlgrastim avoided 10.5 absolute
percentage point of FN (17.5% vs. 7%) at a modest cost increase
(€1306); the incremental cost-effectiveness ratio (ICER) was
€12,429 per FN avoided. The average life expectancy was 15.99
years with pegﬁlgrastim and 15.88 years with ﬁlgrastim, yield-
ing an ICER of €11,972/LYG. Age of diagnosis and cancer stage
had minimal impact on the results. Drug costs and FN risk has
moderate inﬂuence on model results. CONCLUSIONS: In
Germany, pegﬁlgrastim appeared to dominate 11-day ﬁlgrastim
and to be cost-effective within normal thresholds compared with
6-days ﬁlgrastim per cycle.
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OBJECTIVE: To model the cost-effectiveness entecavir (ETV) 
in treating chronic hepatitis B (CHB) in Sweden. METHODS:
Design: A modiﬁed decision tree model was developed to
compare two hypothetical cohorts of CHB patients undergoing
therapy with antiviral agents. Based on patient viral load, the
model estimates the progression to compensated cirrhosis (CC),
decompensated cirrhosis (DC) and hepatocellular carcinoma
(HCC). The multivariate-adjusted risk-predicting models were
developed based on the R.E.V.E.A.L.-HBV Study cohort with
42,115 person-years of follow-up. Perspective: Health care
payer. Patient populations: 1. Nucleoside-naïve patients: 0.5 mg
ETV vs. 100 mg lamivudine (LVD) with adefovir (ADV) admin-
istered as salvage therapy in case of resistance to LVD. 2. LVD-
refractory patients: 1.0 mg ETV vs. 10 mg ADV. Effectiveness:
Efﬁcacy data were used from published clinical trial results. Life-
expectancy was estimated by the DEALE method, using Swedish
life tables. Utility values were obtained by standard gamble in a
CHB health-utility study. Costs: 10-year treatment costs were
estimated using drug acquisition costs published by the LFN.
Costs of CC, DC, and HCC are from a Swedish costing study.
Discounting: Both costs and outcomes were discounted at 3%
annually. Sensitivity analyses were performed to various para-
meters. RESULTS: ETV therapy in nucleoside-naïve patients is a
dominant treatment strategy compared to LVD therapy with
ADV salvage. Cost savings of SEK 8,121,199/SEK 1,1902,137,
QALYs gained 85.70/19.17 for HBeAg-positive/HBeAg–negative
patients, respectively. Treatment with ETV is a dominant treat-
ment strategy compared to ADV in LVD-refractory patients.
Cost savings: SEK 3,612,483, QALYs gained 38.67. Across
patient populations and comparators, ETV was associated with
lower projections of liver-related events, a lower mortality rate
